Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is a Healthcare company (Biotechnology) with a market capitalization of $8.1B. The Maz Rating grades it against the other companies in its sector.
Rhythm Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $116.61, Rhythm Pharmaceuticals, Inc. trades at 28.9x sales and 40.1x book value. Over the last twelve months it generated about $280M of revenue and a net loss of $200M. It runs a gross margin of 88.2%, an operating margin of -66.7% and a net margin of -69.0%. It shows return on equity of -83.7%, return on invested capital of -63.9% and a free cash flow yield of -1.6%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 2.78. Over the past 52 weeks the share price ranged from $74.50 to $122.20, with a beta of 2.13.
Rhythm Pharmaceuticals, Inc. does not currently pay a dividend.
22 Wall Street analyst ratings cover the stock: 22 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.